ESCO2 and neoplasm: The mouse cohort data is consistent with the zebrafish data, in that Esco2 haploinsufficient loss accelerates tumor onset only in a LOH sensitive background (Fig 2B; T50 = 516 days in the Esco2+/-; p53+/- cohort vs. 563 days in the p53+/- cohort; p = 0.0377 based on Log-rank test).